Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed

LONDON, February 26, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), Allergan Inc. (NYSE: AGN), and Depomed Inc. (NASDAQ: DEPO). Free research report on Johnson and Johnson can be accessed at http://get.Investor-Edge.com/pdf/?c=Johnson%20and%20Johnson&d=26-Feb-2015&s=JNJ. On Wednesday, February 25, 2015, the NASDAQ Composite ended at 4,967.14, down 0.02%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,224.57, and the S&P 500 closed at 2,113.86, down 0.08%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 836.10, up 0.01%, with the index also advancing 5.38% in the last three months. Register for your complimentary reports at the links given below.  

On Wednesday, shares in Johnson and Johnson fluctuated between $100.16 and $101.29 before ending the session 0.51% higher at $101.21. The stock reported a trading volume of 9.66 million shares, above its three months average volume of 9.04 million shares. Shares of the company traded at a PE ratio of 16.95. Although, Johnson and Johnson's shares have lost 0.97% in the last one month, it has advanced 0.95% in the previous three trading sessions and 11.09% in the last one year. The company is trading below its 50-day and 200-day moving averages of $102.90 and $103.73, respectively. Moreover, shares of Johnson and Johnson have a Relative Strength Index (RSI) of 47.05. Sign up and read the free notes on JNJ at:

http://get.Investor-Edge.com/pdf/?c=Johnson%20and%20Johnson&d=26-Feb-2015&s=JNJ

Teva Pharmaceutical Industries Ltd's stock edged 0.46% lower, to close the day at $56.52. The stock recorded a trading volume of 4.90 million shares, above its three months average volume of 3.99 million shares. The stock oscillated between $56.17 and $56.67 during the session. Over the last three trading sessions and over the past three months, Teva Pharmaceutical Industries Ltd's shares have fallen by 0.05% and 0.11%, respectively. However, the stock has surged 16.95% in the previous year. The company is trading above its 200-day moving average of $54.33, while the 200-day moving average is below Teva Pharmaceutical Industries Ltd's 50-day moving average of $57.09. Additionally, the stock has an RSI of 47.70. The complimentary notes on TEVA can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Teva%20Pharma%20Industries&d=26-Feb-2015&s=TEVA

On Wednesday, shares in Endo International PLC recorded a trading volume of 2.64 million shares, higher than its three months average volume of 2.58 million shares. The stock ended the day at $85.19, which was 0.07% below its previous day's closing of $85.25, and registered an intraday range of $83.59 and $85.82. Endo International PLC's shares have advanced 8.01% in the last one month, 17.96% in the previous three months and 9.61% in the past one year. The company is trading above its 50-day and 200-day moving averages of $77.62 and $70.04, respectively. Furthermore, shares of Endo International PLC have an RSI of 65.58. Register for free on Investor-Edge and access the latest research on ENDP at:

http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=26-Feb-2015&s=ENDP

Allergan Inc.'s stock edged 0.28% higher, to close Wednesday's session at $232.48, after oscillating between $232.11 and $233.85. The stock recorded a trading volume of 1.88 million shares, below its three months average volume of 2.23 million shares. Over the last one month and the previous three months, Allergan Inc.'s shares have advanced 3.71% and 9.61%, respectively. Additionally, the stock has rallied 85.18% in the last one year. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $219.12 is above its 200-day moving average of $186.31. Further, Allergan Inc.'s stock traded at a PE ratio of 37.21 and has an RSI of 64.31. The complete research on AGN is available for free at:

http://get.Investor-Edge.com/pdf/?c=Allergan&d=26-Feb-2015&s=AGN

Depomed Inc.'s stock finished Wednesday's session 0.84% lower at $22.52. A total of 1.52 million shares were traded, which was above its three months average volume of 1.03 million shares. The stock moved between $22.06 and $22.85 during the session. Over the last one month and the previous three months, Depomed Inc.'s shares have surged 20.30% and 45.01%, respectively. Additionally, the stock has gained 76.63% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $17.58 is greater than its 200-day moving average of $14.68. Depomed Inc.'s stock traded at a PE ratio of 12.13 and has an RSI of 79.75. Free in depth research on DEPO is available at:

http://get.Investor-Edge.com/pdf/?c=Depomed&d=26-Feb-2015&s=DEPO

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.